Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal
Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal
复制标题
DOI：
10.1046/j.1365-2710.2000.00295.x
复制
发表时间：
2000-10-01
影响因子：
2
通讯作者：
Farzanehgan, ZM
中科院分区：
文献类型：
--
作者：
Akhondzadeh, S;Ahmadi-Abhari, SA;Farzanehgan, ZM
背景资料：各种解毒方法已被用于治疗阿片类药物戒断综合征，其中α-肾上腺素能激动剂在过去二十年中引起了相当大的关注。然而，在大鼠中积累的证据表明，GABA（B）受体激动剂，巴氯芬，在减少酒精的摄入量和自我管理cocaine.Objective：为了检查巴氯芬的能力，在阿片类药物戒断的管理。方法：共62阿片类药物成瘾者随机分配到治疗与巴氯芬或可乐定在14天，双盲临床试验。所有患者均符合DSM IV阿片类药物依赖标准。巴氯芬的最大日剂量为40 mg，可乐定为0.8 mg，每日分三次给药。结果：巴氯芬和可乐定对阿片类戒断综合征的躯体症状有相同的治疗效果。结论：巴氯芬可能是阿片类戒断综合征的一种新的治疗药物。然而，一个更大的研究来证实我们的结果是必要的。
Background: A variety of detoxification methods have been utilized for the treatment of opiate withdrawal syndrome, of which alpha-adrenergic agonists have attracted considerable attention over the last two decades. However, accumulating evidence in rats shows the efficacy of the GABA(B) receptor agonist, baclofen, in reducing alcohol intake and self-administration of cocaine.Objective: To examine the ability of baclofen, in the management of opiate withdrawal.Method: A total of 62 opiate addicts randomly assigned to treatment with baclofen or clonidine during a 14-day, double-blind clinical trial. All patients met the DSM IV criteria for opioid dependence. Maximum daily doses were 40 mg for baclofen and 0.8 mg for clonidine given three times a day in divided doses. The severity of the opiate withdrawal syndrome was measured on days 0, 1, 2, 3, 4, 7 and 14 using the Short Opiate Withdrawal Scale (SOWS).Results: Baclofen and clonidine were equally effective in treating the physical symptoms of withdrawal syndromes. However, baclofen showed a significant superiority over clonidine in the management of mental symptoms.Conclusion: These results suggest that baclofen might be a novel therapeutic agent for opiate withdrawal syndrome. However, a larger study to confirm our results is warranted.